抑癌基因甲基化与肺癌(3)

DNA甲基化与肺癌发生发展的关系是近年研究较热的课题。目前对DNA甲基化的研究还处在起步阶段，DNA甲基化发生的原因及确切机理还不清楚，肿瘤抑癌基因甲基化与肺癌间的对应关系还不明确。随着越来越多的与肺癌相关的异常甲基化基因的发现和研究，肺癌特异性的分子标记物的联合检测为肺癌的早期诊断提供了新的思路。而表观遗传修饰的可逆转，为肺癌治疗新途径的探索提供了启示和方向。因此，对与肺癌相关抑癌基因甲基化的进一步研究具有十分美好的前景。 【参考文献】

[1] Nakata S,Sugio K,Uramoto H，et al. The methylation status and protein expression of CDH1，pl6(INK4A)，and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic

DOC格式论文，方便您的复制修改删减

silencing，clinical features,and Prognostie significance[J]. Cancer,2006,106(10):2190～2199.

[2] Palmisano WA,Dvine KK,Saccomanno G,et al. Predicting lung cancer by detecting aberrant promoterm ethylation in sputum[J]. Cancer Res,2000,60: 5954～5958.

[3] Liu Y,Lan Q,Gao W,et al. Promoter methylation of RASSF1A and DAPK and mutations of K

ras and p53 in non

small

cell lung cancer patients[J]. Proc Amer Assoc Cancer Res,2006,47.

[4] 余宗涛，袁亚莉，张吉才，等. 肺癌组织细胞 FHIT 基因启动子甲基化和转录表达 [J]. 肿瘤防治研究，2007,34(7):498～500.

[5] Tran YK,Bogler O,Gorse KM,et al. A novel member of the NF2/ERM/4.1 superfamily with growth suppressing properties in lung cancer[J]. Cancer Res,1999,59: 35～43.

[6] Shinji K,Daisuke Y,Takeshi F,et al. Promoter methylation of DAL

1/4.1B predicts poor prognosis in